134 related articles for article (PubMed ID: 38626739)
1. Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria.
Keskinkaya Z; Kaya Ö; Işık Mermutlu S; Öğretmen Z
Int Arch Allergy Immunol; 2024 Apr; ():1-8. PubMed ID: 38626739
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.
Chen Y; Yu M; Huang X; Tu P; Shi P; Maurer M; Zhao Z
World Allergy Organ J; 2021 Jan; 14(1):100501. PubMed ID: 33510832
[TBL] [Abstract][Full Text] [Related]
3. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of recurrence after omalizumab cessation in the elderly with urticaria: A real-life study.
Oztop N; Demir S; Unal D; Beyaz S; Terzioglu K; Olgac M; Gelincik A
Allergy Asthma Proc; 2022 Nov; 43(6):519-528. PubMed ID: 36335414
[No Abstract] [Full Text] [Related]
6. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria.
Asero R; Marzano AV; Ferrucci S; Lorini M; Carbonelli V; Cugno M
Clin Exp Immunol; 2020 Jun; 200(3):242-249. PubMed ID: 32115683
[TBL] [Abstract][Full Text] [Related]
7. Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
Asero R; Ferrucci SM; Calzari P; Consonni D; Cugno M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108654
[TBL] [Abstract][Full Text] [Related]
8. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients.
Türk M; Yılmaz İ; Bahçecioğlu SN
Allergol Int; 2018 Jan; 67(1):85-89. PubMed ID: 28566225
[TBL] [Abstract][Full Text] [Related]
9. IgG and IgE Autoantibodies to IgE Receptors in Chronic Spontaneous Urticaria and Their Role in the Response to Omalizumab.
Maronese CA; Ferrucci SM; Moltrasio C; Lorini M; Carbonelli V; Asero R; Marzano AV; Cugno M
J Clin Med; 2023 Jan; 12(1):. PubMed ID: 36615181
[No Abstract] [Full Text] [Related]
10. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
[TBL] [Abstract][Full Text] [Related]
11. The autologous serum skin test (ASST) predicts the response to anti-IgE treatment in Chronic Spontaneous Urticaria patients: a prospective study.
Palladino A; Villani F; Pinter E; Visentini M; Asero R
Eur Ann Allergy Clin Immunol; 2024 Mar; ():. PubMed ID: 38482859
[No Abstract] [Full Text] [Related]
12. Autoimmune chronic spontaneous urticaria.
Kolkhir P; Muñoz M; Asero R; Ferrer M; Kocatürk E; Metz M; Xiang YK; Maurer M
J Allergy Clin Immunol; 2022 Jun; 149(6):1819-1831. PubMed ID: 35667749
[TBL] [Abstract][Full Text] [Related]
13. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
14. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
[TBL] [Abstract][Full Text] [Related]
15. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
Brás R; Costa C; Limão R; Caldeira LE; Paulino M; Pedro E
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2392-2402. PubMed ID: 36720390
[TBL] [Abstract][Full Text] [Related]
17. An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria.
Lal Vijayalal S; Arora S; Dabas R; Janney MS; Jankal Basavarajappa S; Das NM
Dermatol Ther; 2020 Nov; 33(6):e14397. PubMed ID: 33040395
[TBL] [Abstract][Full Text] [Related]
18. IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria?
Altrichter S; Peter HJ; Pisarevskaja D; Metz M; Martus P; Maurer M
PLoS One; 2011 Apr; 6(4):e14794. PubMed ID: 21532759
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab in severe chronic urticaria: are slow and non-responders different?
Asero R
Eur Ann Allergy Clin Immunol; 2021 Nov; 53(6):263-266. PubMed ID: 32914943
[No Abstract] [Full Text] [Related]
20. Increased serum free IgE levels in patients with chronic spontaneous urticaria (CSU).
Jang JH; Yang EM; Lee Y; Ye YM; Moon J; Ryu MS; Park HS
World Allergy Organ J; 2022 Feb; 15(2):100629. PubMed ID: 35280503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
